Zacks Research Analysts Lift Earnings Estimates for HALO

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Zacks Research lifted their Q1 2025 earnings estimates for Halozyme Therapeutics in a research note issued on Tuesday, December 10th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn $0.97 per share for the quarter, up from their previous forecast of $0.95. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.80 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q4 2025 earnings at $1.30 EPS, Q1 2026 earnings at $1.40 EPS and Q2 2026 earnings at $1.41 EPS.

HALO has been the topic of several other research reports. HC Wainwright reiterated a “buy” rating and issued a $68.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, November 20th. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Wells Fargo & Company cut shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $58.00 to $62.00 in a report on Monday, October 7th. JMP Securities raised their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Finally, JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their price objective for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $61.11.

Halozyme Therapeutics Stock Up 0.9 %

Shares of HALO opened at $47.83 on Thursday. The firm has a 50 day simple moving average of $51.65 and a two-hundred day simple moving average of $53.89. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. Halozyme Therapeutics has a one year low of $33.15 and a one year high of $65.53. The company has a market cap of $6.09 billion, a P/E ratio of 15.84, a P/E/G ratio of 0.44 and a beta of 1.23.

Insider Buying and Selling at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $62.03, for a total value of $620,300.00. Following the transaction, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at $10,778,084.68. The trade was a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 40,000 shares of company stock worth $2,242,100. 2.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. International Assets Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth $33,000. Skandinaviska Enskilda Banken AB publ bought a new stake in Halozyme Therapeutics during the second quarter valued at $49,000. GAMMA Investing LLC grew its holdings in Halozyme Therapeutics by 67.7% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 350 shares during the period. Toth Financial Advisory Corp acquired a new stake in Halozyme Therapeutics during the 3rd quarter worth about $57,000. Finally, FSC Wealth Advisors LLC bought a new position in shares of Halozyme Therapeutics in the 3rd quarter worth about $65,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.